Analyst Price Targets — CMPGY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 14, 2026 11:16 am | Ed Engel | Compass Point | $51.00 | $30.89 | StreetInsider | Compass Point Upgrades Bullish (BLSH) to Buy |
| September 10, 2026 8:35 am | Jaafar Mestari | Compass Point | $36.00 | $30.46 | TheFly | Compass Group upgraded to Outperform from Neutral at BNP Paribas |
| September 9, 2026 11:49 am | Giuliano Bologna | Compass Point | $42.00 | $30.37 | StreetInsider | Chime Financial (CHYM) PT Raised to $42 at Compass Point |
| August 14, 2026 11:27 am | Ed Engel | Compass Point | $30.00 | $32.70 | StreetInsider | Bullish (BLSH) PT Raised to $30 at Compass Point |
| July 15, 2026 10:05 am | — | Compass Point | $15.00 | $31.73 | StreetInsider | Compass Inc. (COMP) PT Raised to $15 at BTIGMember Login |
| July 9, 2026 11:32 am | — | Compass Point | $40.00 | $32.25 | StreetInsider | Galaxy Digital (GLXY) PT Lowered to $40 at Compass PointMember Login |
| June 15, 2026 10:56 am | Michael Donovan | Compass Point | $90.00 | $34.22 | StreetInsider | Compass Point Reiterates Buy Rating on SharonAI Holdings Inc (SHAZ) |
| May 26, 2026 11:33 am | Michael Donovan | Compass Point | $50.00 | $31.29 | StreetInsider | WhiteFiber Inc (WYFI) PT Raised to $50 at Compass Point |
| February 9, 2026 2:26 pm | Stephen Ju | UBS | $17.00 | $28.38 | StreetInsider | Compass Inc. (COMP) PT Raised to $17 at UBS: 'improving momentum into year-end' |
| December 10, 2024 1:18 pm | David Rochester | Compass Point | $83.00 | $34.56 | TheFly | Wells Fargo price target raised to $83 from $60 at Compass Point |
Latest News for CMPGY
How a court case and listing battle is shaping up.
Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling.
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.
Compass Pathways NASDAQ: CMPS said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD.
Compass Pathways NASDAQ: CMPS expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global Healthcare Conference.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CMPGY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.